Jocelyn Aspa

Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.

Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.


5 Top NASDAQ Genetics Stocks of 2019

As 2019 comes to a close, the Investing News Network is profiling the five top genetics stocks on the NASDAQ...

December 9th, 2019

5 Top Medical Device News Stories of 2019

What was the top medical device news of 2019? Here's a list of our top headlines this year, according to...

December 9th, 2019

Mustang Bio Announces Additional Clinical Data on MB-107

The company announced that updated Phase 1/2 clinical data for MB-107 was presented at the 61st American Society of Hematology...

December 9th, 2019

Abeona Therapeutics to Initiate Phase 3 Clinical Trial of B-101

The company announced that the US Food and Drug Administration has removed its clinical hold on its Phase 3 clinical...

December 9th, 2019

Ocugen Completes 50 Percent Enrollment in Phase 3 Clinical Trial

The company announced 50 percent of enrollment in its Phase 3 clinical trial for OCU300 has been completed.

December 9th, 2019

Achillion Reports Positive Data from Phase 2 Study of Danicopan

The company announced results at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

December 9th, 2019

Aprea Therapeutics Presents Data from Phase 1b/2 Clinical Trial of APR-246

The company announced results at the 2019 ASh Annual Meeting for its French Phase 1b/2 clinical trial of APR-246.

December 9th, 2019